A Phase 3 interventional study of epoetin alfa and epoetin alfa in Anemia and Renal Diseases, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 66 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 126 studies testing Epoetin Alfa in Anemia — 2 open to participants now, 3 under way, 2 of them phase 3. Epoetin Alfa · Anemia.
Among the 126 studies testing Epoetin Alfa in Anemia, this one is the 8th largest by enrollment of the 112 interventional ones that give a count, is one of 5 that started in 2007, is one of 45 in phase 3, and was the 89th registered.
1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.
Browse Anemia studies →2 of the 126 studies testing Epoetin Alfa in Anemia are open now, in 1 country. Recruiting first, the newest first:
Services Hospital, Lahore · Sites in Pakistan
Ages 18–65
Geoff Block
Ages 18+
By country, each count listing its studies:
Epoetin Alfa: first FDA approval 1989 (EPOGEN/PROCRIT), first EMA approval 1997. What it is approved for, and how studies give it, is on its page →
Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
126 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 45 · Phase 3 46 · Phase 4 20
First in 1988; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 430 is above the median of 117 across 1,336 interventional studies indexed under Anemia.
Median enrollment 71 across the 112 interventional studies. Of the 114 that completed or were terminated, 23 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
95 of 126 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
77 studies in Anemia by Johnson & Johnson: none open now, none under way, none of them phase 3. Of 74 finished, 9 (12%) have results posted.
Among the 77 studies in Anemia by Johnson & Johnson, this one is the 8th largest by enrollment of the 62 interventional ones that give a count, is one of 2 that started in 2007, is one of 26 in phase 3, and was the 65th registered.
Johnson & Johnson’s Anemia studies by the year they started, since 1988.
2 of the studies testing Epoetin Alfa in Anemia that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07565701Phase 3Geoff BlockSafety and Efficacy of a Phased Transition From Epogen to Three Times Weekly Oral Vadadustat for the Treatment of Anemia in Subjects Receiving In-Center Hemodialysis | 2027-04 |
| NCT07755683Services Hospital, LahoreEffect of Daprodustat and Epoetin Alpha on Anemia in Patients Not Undergoing Dialysis | 2027-02-28 |
Add all 2 to your calendar (.ics) → With an account.
Among the 126 studies testing Epoetin Alfa in Anemia, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 77 in Anemia:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to demonstrate that once every-2-weeks and once every-4-weeks treatment with epoetin alfa, a drug that increases red blood cell production, in patients with anemia associated with chronic kidney disease, is not less effective than treatment with epoetin alfa that is given once a week
A consequence of chronic kidney disease is anemia due to decreased production of erythropoietin. Anemia is associated with decreased oxygen delivery and utilization, and can result in fatigue, lethargy, decreased cognition and mental acuity, and cardiac complications.This study was designed to compare 2 dosing regimens, once every-2-weeks and once every-4-weeks with the once-weekly dosing regimen. Men and women who are diagnosed with anemia associated with chronic kidney disease will participate in this study. Approximately 400 patients will be included. This is a randomized (patients are assigned different treatments based on chance), open-label, multicenter study of epoetin alfa in patients who are not on dialysis and who are already maintaining anemia with epoetin alfa administered once weekly. The study is 40 to 42 weeks in duration. All eligible patients will be treated with epoetin alfa according to one of the following 3 regimens: once-a-week injection (Group 1), or once every-2-weeks injection (Group 2), or once every-4-weeks injection (Group 3). The maximum volume per injection will not be more than 1 mL, therefore some patients may receive more than one injection per dose. The study treatment includes a period to convert to the new dosing regimen, and a subsequent stable maintenance treatment period. After the initial dose, hemoglobin will be measured on a weekly basis and used to determine adjustments in dose for each patient. The primary hypothesis is that the average change in hemoglobin level in the groups that received epoetin alfa once every 2 weeks or once every 4 weeks is not lower than the change in hemoglobin level in the group that received epoetin alfa only once a week. Adverse events will be monitored throughout the study. Clinical laboratory examinations, vital signs, and physical examinations will be conducted routinely to ensure patient safety. Approximately 1 mL of epoetin alfa will be injected under the skin either once a week, once every 2 weeks, or once every 4 weeks (maximum doses of 20,000 IU once a week, 40, 000 IU every 2 weeks, or 80,000 IU every 4 weeks, respectively) for up to 36 weeks of treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
epoetin alfa Continue pre-study once weekly dose of epoetin alfa for 36 weeks
Drug: epoetin alfa
epoetin alfa Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
Drug: epoetin alfa
epoetin alfa Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
Drug: epoetin alfa
Continue pre-study once weekly dose of epoetin alfa for 36 weeks
Double the pre-study once weekly dose of epoetin alfa every 2 weeks for 36 wks
Quadruple the pre-study once weekly dose of epoetin alfa every 4 weeks for 36 wk
Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment
Time frame: from baseline (Week 1) to the last 12 weeks of treatment
Proportion of Weeks Per Patient With Hemoglobin Concentration Between 10.0 and 11.9 Grams Per Deciliter (g/dL)
Time frame: Weeks 13-37
Participants Who Exceeded a Hemoglobin Concentration of 11.9 Grams Per Deciliter (g/dL)
Time frame: 36 weeks of treatment
Maximum Hemoglobin Concentration in Grams Per Deciliter (g/dL)
Time frame: 36 weeks of treatment
Participants Who Met or Exceeded 1.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
Time frame: 36 weeks of treatment
Participants Who Met or Exceeded 1.5 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
Time frame: 36 weeks of treatment
Participants Who Met or Exceeded 2.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise
Time frame: 36 weeks of treatment
Maximum Hemoglobin Rate of Rise in Grams Per Deciliter (g/dL/2 Weeks)
Time frame: 36 weeks of treatment
Number of Participants Who Died
Time frame: 36 weeks of treatment
| Milestone | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Started | 108 | 107 | 215 |
| Completed | 95 | 92 | 174 |
| Not completed | 13 | 15 | 41 |
| Withdrew: Death | 3 | 2 | 9 |
| Withdrew: Adverse event | 3 | 4 | 11 |
| Withdrew: Lost to follow-up | 1 | 0 | 2 |
| Withdrew: Physician decision | 2 | 0 | 1 |
| Withdrew: Protocol violation | 2 | 0 | 4 |
| Withdrew: Withdrawal by subject | 2 | 5 | 9 |
| Withdrew: Began dialysis | 0 | 0 | 1 |
| Withdrew: Met hemoglobin withdrawal criteria | 0 | 4 | 4 |
| g/dL | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Change in Hemoglobin Concentration in Grams Per Deciliter (g/dL) From Baseline to the Average of the Last 12 Weeks of Treatment | -0.02 ± 0.728 | -0.10 ± 0.774 | -0.19 ± 0.738 |
| Proportion | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Proportion of Weeks Per Patient With Hemoglobin Concentration Between 10.0 and 11.9 Grams Per Deciliter (g/dL) | 0.87 (0.3 to 1.0) | 0.88 (0.0 to 1.0) | 0.83 (0.0 to 1.0) |
| Participants | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Participants Who Exceeded a Hemoglobin Concentration of 11.9 Grams Per Deciliter (g/dL) | 79 | 89 | 161 |
| g/dL | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Maximum Hemoglobin Concentration in Grams Per Deciliter (g/dL) | 12.35 ± 0.828 | 12.48 ± 0.760 | 12.46 ± 0.988 |
| Particpants | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Participants Who Met or Exceeded 1.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise | 84 | 91 | 191 |
| Participants | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Participants Who Met or Exceeded 1.5 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise | 52 | 57 | 124 |
| Participants | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Participants Who Met or Exceeded 2.0 Grams Per Deciliter Per 2 Weeks (g/dL/2 Weeks) Hemoglobin Rates of Rise | 37 | 33 | 68 |
| g/dL/2 weeks | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Maximum Hemoglobin Rate of Rise in Grams Per Deciliter (g/dL/2 Weeks) | 1.77 ± 1.068 | 1.69 ± 0.790 | 1.81 ± 1.173 |
| Participants | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Number of Participants Who Died | 4 | 3 | 9 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Epoetin Alfa QW | — | 24/108 (22.2%) | 59/108 (54.6%) |
| Epoetin Alfa Q2W | — | 28/107 (26.2%) | 59/107 (55.1%) |
| Epoetin Alfa Q4W | — | 56/215 (26%) | 116/215 (54%) |
| Event | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| Cardiac failure congestiveCardiac disorders | 5/108 | 8/107 | 4/215 |
| Renal failure acuteRenal and urinary disorders | 5/108 | 5/107 | 1/215 |
| AnaemiaBlood and lymphatic system disorders | 2/108 | 4/107 | 1/215 |
| Chest painGeneral disorders | 4/108 | 2/107 | 3/215 |
| DehydrationMetabolism and nutrition disorders | 3/108 | 2/107 | 0/215 |
| Acute myocardial infarctionCardiac disorders | 1/108 | 2/107 | 0/215 |
| Renal failure chronicRenal and urinary disorders | 0/108 | 2/107 | 1/215 |
| Pulmonary oedemaRespiratory, thoracic and mediastinal disorders | 1/108 | 2/107 | 1/215 |
| Myocardial infarctionCardiac disorders | 2/108 | 0/107 | 2/215 |
| Sudden cardiac deathGeneral disorders | 2/108 | 0/107 | 0/215 |
| Event | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W |
|---|---|---|---|
| HypertensionVascular disorders | 11/108 | 14/107 | 24/215 |
| OedemaGeneral disorders | 5/108 | 13/107 | 16/215 |
| Urinary tract infectionInfections and infestations | 12/108 | 8/107 | 13/215 |
| Oedema peripheralGeneral disorders | 6/108 | 10/107 | 14/215 |
| HyperkalaemiaMetabolism and nutrition disorders | 7/108 | 7/107 | 18/215 |
| DizzinessNervous system disorders | 3/108 | 7/107 | 18/215 |
| DiarrhoeaGastrointestinal disorders | 8/108 | 5/107 | 14/215 |
| ConstipationGastrointestinal disorders | 5/108 | 5/107 | 15/215 |
| FatigueGeneral disorders | 6/108 | 5/107 | 15/215 |
| NasopharyngitisInfections and infestations | 4/108 | 6/107 | 15/215 |
| Age, Categorical(Participants) | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W | Total |
|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 33 | 26 | 57 | 116 |
| >=65 years | 75 | 81 | 158 | 314 |
| Age, Continuous(years) | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W | Total |
|---|---|---|---|---|
| Mean | 70.3 ± 13.04 | 71.7 ± 10.63 | 71.1 ± 12.48 | 71 ± 12.18 |
| Sex: Female, Male(Participants) | Epoetin Alfa QW | Epoetin Alfa Q2W | Epoetin Alfa Q4W | Total |
|---|---|---|---|---|
| Female | 68 | 73 | 126 | 267 |
| Male | 40 | 34 | 89 | 163 |
The record gives a start of Jul 2007, a primary completion of Mar 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2011, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Epoetin Alfa
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →